Background: Although increased accumulation of neutrophils has been noted in chronic rhinosinusitis (CRS), the function and regulation of neutrophils in CRS are largely unknown. IL-36 family cytokines may play an important role in neutrophilic inflammation.
Chronic rhinosinusitis (CRS) is an inflammatory disease of the mucosa of the nose and paranasal sinuses. Based on the presence or absence of formation of polyps, CRS is classified into 2 phenotypes, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP).
1,2 Both CRSsNP and CRSwNP are characterized by loss of immune barrier and infiltration of diverse immune cells. [3] [4] [5] Type 2 inflammation and eosinophilia have been revealed to play an important role in the development of CRSwNP 1, 2, 6, 7 ; however, we found that neutrophil infiltration was also enhanced in CRSwNP, both eosinophilic and noneosinophilic type in Chinese patients. 8, 9 It has also been reported that nasal polyps, which are highly eosinophilic, also have significant levels of neutrophils in white patients. 10, 11 IL-8 (chemokine [C-X-C motif] ligand 8 [CXCL8]) levels are upregulated in polyps of patients not only from China but also from Europe. 11, 12 Additionally, we and other groups discovered upregulated type 17 responses in Chinese CRSwNP patients. 12, 13 As regards CRSsNP, it is generally even more neutrophilic and type-1/type-17 response dominant compared with CRSwNP. 9, 12, 13 However, the function and regulation of neutrophilic inflammation in CRS remain largely unknown. Limited studies have shown that neutrophils may contribute to tissue remodeling and impaired epithelial barrier in CRS through producing TGF-b2 and oncostatin M. 9, 10 To further clarify the function and regulation of neutrophilic inflammation in CRS may have significant clinical implications because neutrophilic inflammation may reduce the response to corticosteroid treatment in patients with CRSwNP.
14 IL-36a, IL-36b, IL-36g, and IL-36 receptor antagonist (IL36Ra) belong to the recently identified IL-36 cytokine family, which is grouped into the IL-1 family. 15 IL-36 cytokines bind to a specific IL-36 receptor complex composed of a unique IL-36R (also known as IL-1RL2) and a coreceptor IL-1R accessory protein (IL-1RAcP). 16 IL-38 can also bind to IL-36R and likely belongs to IL-36 family. 15 IL-36 family cytokines are produced by immune cells, neuron cells, keratinocytes, and bronchial epithelial cells. [17] [18] [19] [20] [21] [22] Although IL-1RAcP is ubiquitously expressed, IL-36R has been primarily found on skin keratinocytes, fibroblasts, glial cells, and some immune cells. 16, 19, [22] [23] [24] IL-36a, IL-36b, and IL-36g act as agonists for IL-36R, leading to nuclear factor-kB pathway activation and subsequent IL-6 and IL-8 production. 19, 21, 23, 25 In contrast, IL-36Ra and IL-38 competitively bind to IL-36R, but they cannot engage IL-1RAcP, thus they function as antagonists for IL-36R signaling. [26] [27] [28] Recently, IL-36 cytokines have been found to promote neutrophil infiltration in psoriasis through inducing neutrophil chemokine production from keratinocytes. 29 However, whether they play a role in neutrophilic inflammation in CRS is not known.
In the current study, we investigated the involvement of IL-36 in CRS and discovered that IL-36g is upregulated and activated in CRS and potentially promotes neutrophilic inflammation by directly acting on neutrophils in CRS.
METHODS

Subjects and specimens
This study was approved by the Ethics Committee of Tongji Hospital and was conducted with written informed consent from every patient. A total of 27 CRSsNP patients, 191 CRSwNP patients, and 102 control subjects were enrolled in this study. The diagnosis of CRS was made according to the current European and American guidelines.
1,2 CRSwNP was defined as eosinophilic when the percentage of tissue eosinophils exceeded 10% of total infiltrating cells as reported by us. 13 This cutoff was calculated as twice the standard deviation of the mean of eosinophil percentage in controls. 13 Subjects undergoing septoplasty because of anatomic variations and without other sinonasal diseases were enrolled as control subjects. 13, 30 During surgery, diseased ethmoid sinus mucosal samples from CRSsNP patients, polyp tissues from CRSwNP patients, and inferior turbinate mucosal tissues from control subjects were collected. Human nasal epithelial cells (HNECs) were scraped from inferior turbinate of controls as previously described. 31 More information is provided in the Online Repository including Tables E1 and E2 (at  www. jacionline.org).
Histology and immunohistochemistry
Hematoxylin and eosin staining, immunohistochemical and immunofluorescence staining with specific primary antibodies, and cell quantification were performed as previously described. 13, 32 More information is provided in the Online Repository including Tables E3 and E4 (at www.jacionline.org).
In situ hybridization
Nasal polyp sections were analyzed for IL-36g mRNA expression by in situ hybridization as described previously. 33 More information is provided in the Online Repository (at www.jacionline.org).
Quantitative RT-PCR
Quantitative RT-PCR was performed with specific primers (see Table E5 in this article's Online Repository at www.jacionline.org), as stated elsewhere. 30, 34 GUSB served as a housekeeping gene for normalization. More information is provided in the Online Repository.
HNEC culture
HNECs were cultured with an air-liquid interface method as mentioned elsewhere. 31, 32, 35, 36 Cells were treated with various stimulators for 6 hours and then harvested for further quantitative RT-PCR. More information is provided in the Online Repository.
Peripheral blood neutrophil isolation and culture
Peripheral blood neutrophils were purified by using Ficoll and 3% dextran (Tianjin Haoyang Biological Manufacture, Tianjin, China) as previously described. 29, 37 Isolated neutrophils were cultured and stimulated with various mediators. After 6 hours and 20 hours of stimulation, cells were harvested for quantitative RT-PCR and flow cytometry, respectively. In some experiments, culture supernatants were harvested for elastase activity assay. More information is provided in the Online Repository.
Flow cytometry
Dispersed nasal polyp cells (DNPCs) were prepared by dissociating tissues mechanically as previously reported. 34 Flow cytometric analysis of purified blood neutrophils, DNPCs depleted of mononuclear cells, and mononuclear cells from peripheral blood and nasal polyps was performed as previously described. 10, 24 Mononuclear cells were isolated by density gradient centrifugation over Ficoll (Tianjin Haoyang Biological Manufacture). 34 More information is provided in this article's Online Repository including Table E6 (at www.jacionline.org).
Nasal tissue elutes
Freshly obtained polyp and control tissues were weighed and 0.5 mL of protease reaction buffer (50 mmol/L HEPES [pH 7.2]/75 mmol/L NaCl/0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) was added for every 100 mg of tissue. 32 The tissues were eluted with protease reaction buffer under constant rotation for 1 hour at 48C as previously described. 38 Tissue elutes were collected and stored at -808C for further study. The protein levels in elutes were quantified by a BCA protein detection kit (Guge Biotechnology, Wuhan, China).
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IL-36g cleavage assay and Western blotting analysis
Human recombinant full-length IL-36g (2 mg, 18.7 KDa; R&D Systems, Minneapolis, Minn) was preincubated with 1 mg/mL control BSA (Boster Biotechnology, Wuhan, China), 1 mg/mL polyp elutes, or 50 to 200 nmol/L elastase (Enzo Life Sciences, Farmingdale, NY) for 2 hours. In some experiments, IL-36g was incubated with 200 nmol/L elastase in the presence of 10 mmol/L elastase inhibitor IV (Calbiochem, Shanghai, China) or 1% proteinase inhibitor cocktail (Boster Biotechnology). 38, 39 Western blotting analysis of IL-36g was conducted as previously reported. 19 More information is provided in the Online Repository.
Protease activity assays
The detection of activity of elastase in nasal tissue elutes, DNPC supernatants, and neutrophil culture supernatants was carried out with a commercial kit (Biovision, Milpitas, Calif) according to the manufacturer's instruction. More information is provided in the Online Repository.
DNPC culture
DNPCs depleted of mononuclear cells were cultured as previously described 40 and treated with N-terminally truncated mature human IL-36g (aa18-169) or full-length human IL-36g (aa1-169) (R&D Systems). In some experiments, 10 mmol/L elastase inhibitor IV (Calbiochem) or dexamethasone (10 27 mol/L; Sigma-Aldrich, St Louis, Mo) was added to culture. After 6 hours and 24 hours of stimulation, cells and culture supernatants were harvested for further analysis, respectively. More information is provided in the Online Repository.
Cytokine measurement
Cytokine concentrations in supernatants of cultured DNPCs and tissue homogenates were measured by means of Bio-Plex suspension chip technology or with commercial ELISA kits. 12, 41, 42 Eosinophilic cationic protein (ECP) level in tissue homogenates was measured by using the UniCAP system (Pharmacia, Uppsala, Sweden). 12, 41 The lower detection limits are listed in Tables E7 and Table E8 in this article's Online Repository at www. jacionline.org. More information is provided in the Online Repository.
Statistical analysis
Expression data are presented in dot plots unless specifically indicated. Symbols represent individual samples; horizontal bars represent median, and error bars show interquartile range. The Kruskal-Wallis H test was used to assess significant intergroup variability and the MannWhitney U 2-tailed test was used for between-group comparison. Chisquare test or Fisher exact test was applied to compare the difference J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 in proportions between groups. Cell culture data are expressed as mean 6 SEM and analyzed by unpaired Student t test. Significance was accepted at P < .05.
RESULTS
Type-1/type-2/type-17 cytokine profiles in CRS IL-5 and ECP levels were significantly increased in patients with eosinophilic CRSwNP compared with those of patients with noneosinophilic CRSwNP and CRSsNP and controls (see Fig E1, A and B in this article's Online Repository at www.jacionline. org). IL-17, IFN-g, and myeloperoxidase (MPO) concentrations were increased in all types of CRS in comparison with controls ( Fig E1, A and B) . The upregulation of IFN-g and MPO was more prominent in CRSsNP than in CRSwNP (Fig E1, A and B) . We further assessed the positivity of IL-5, IL-17, and IFN-g as previously reported. 12 The total positivity for IL-5, IL-17, and IFN-g was 49%, 55%, and 58% in CRSwNP group (Fig E1, C) , respectively, suggesting a type-2/type-1 and type-2/type-17 mixed pattern for CRSwNP from our area (Wuhan, China). The total IL-5, IL-17, and IFN-g positivity in patients with CRSsNP was 18%, 44%, and 69%, respectively (Fig E1, D) . Moreover, we evaluated the ECP/ MPO ratio in CRS patients in our area as previously described. 12 We found that about 42% of CRSwNP patients and 18% of CRSsNP patients demonstrated an ECP/MPO ratio > 1 (Fig E1, E) .
Upregulated mRNA expression of IL-36 family members and IL-36R in CRS
We first found that the mRNA expression of all IL-36 family members including IL-36a, IL-36b, IL-36g, IL-36Ra, IL-38, and IL-36R were comparably upregulated in eosinophilic and noneosinophilic CRSwNP and CRSsNP in comparison with controls (Fig 1, A) . We compared the relative abundance of different IL-36 members in sinonasal mucosa as reflected by DCt values (DCt 5 the difference in threshold cycles for target and housekeeping gene GUSB). 43 The high DCt value indicates the low expression in target mRNA. 43 We found that IL-36g was the most abundant isoform in CRS (Fig 1, B) . Because both agonists and antagonists of IL-36R were upregulated in CRS, we calculated the gene expression ratio of agonist/antagonist based on the most abundantly expressed IL-36. We found that a higher ratio of IL-36g/IL-36Ra in eosinophilic and noneosinophilic CRSwNP and CRSsNP and a higher ratio of IL-36g/IL-38 in eosinophilic CRSwNP than those in controls (Fig 1, C) .
Upregulated protein levels and cellular distribution of IL-36 family members and IL-36R in CRS
Consistent with results of RT-PCR study, we found increased protein levels of IL-36 family members in all types of CRS compared with controls and IL-36g was the most abundant expressed isoform in CRS (Fig 2, A) . Also, we found a higher ratio of IL-36g/IL-36Ra protein level in all types of CRS and a higher ratio of IL-36g/IL-38 protein level in CRSwNP than those in controls (Fig 2, B) .
Immunohistochemistry was next employed to study the tissuespecific cellular provenance of IL-36 family members and IL-36R. We found that the immunoreactivity of IL-36a, IL-36b, and IL-38 was mainly located in inflammatory cells in lamina propria, despite the faint staining in epithelium (see Fig E2, A, B , and D in this article's Online Repository at www.jacionline.org). The immunoreactivity of IL-36Ra was found in endothelial cells of blood vessels (Fig E2, C) . Importantly, IL-36g was mainly expressed by nasal epithelial cells although a weak expression was discovered in inflammatory cells in lamina propria (Fig 2, C) . A previous study reported IL-36g expression by neutrophils in central nervous system in experimental autoimmune encephalomyelitis mice. 44 In this study, by using in situ hybridization combined with immunohistochemistry, we found that some neutrophils had IL-36g expression in nasal polyps (see Fig E3 in J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 www.jacionline.org). As to IL-36R, the immunoreactivity was mainly found in inflammatory cells (Fig 2, C) . The numbers of IL-36a-, IL-36b-, IL-38-, and IL-36R-positive cells in lamina propria and staining intensity of IL-36g in nasal epithelium and IL-36Ra in lamina propria were increased in all types of CRS as compared with controls (Fig 2 and Fig E2) .
Regulation of IL-36 expression in HNECs
In line with the findings in bronchial epithelial cells, 19 we found that IL-36g mRNA expression in normal HNECs was upregulated by double-stranded RNA, IL-1b, TNF-a, and IL-17A (see Fig E4, A in this article's Online Repository at www. jacionline.org). As to other IL-36 members, consistent with immunohistochemistry findings, a weaker mRNA expression was detected in HNECs (Fig E4, C) , which was not changed after stimulation (Fig E4, B) .
IL-36R is predominantly expressed on neutrophils in nasal polyps
Given the larger amount of tissue samples generally obtained from CRSwNP patients compared with CRSsNP patients, we studied function of IL-36g in nasal polyps thereafter. We first performed immunofluorescence staining with antibodies against IL-36R and hematopoietic cell-specific markers to define the cell types expressing IL-36R. We did not observe obvious colocalization of IL-36R with CD4
1 T cells, CD8 1 cells in nasal polyps (Fig 3, A-C) . On the other hand, about 68% of polyp neutrophils had IL-36R expression (Fig 3, A-C) . To a lesser extent, IL-36R was also identified on major basic protein-positive eosinophils and CD11c 1 dendritic cells (Fig E5) . Consistent with our previous reports, 8, 9 we found that the number of MPO 1 neutrophils was elevated in both eosinophilic and noneosinophilic polyps compared with controls (Fig 3, D) . In addition, we discovered that the number of IL-36R 1 MPO 1 neutrophils was increased in both eosinophilic and noneosinophilic polyps compared with controls (Fig 3, D) .
Because a previous study did not find obvious expression of IL-36R on peripheral blood neutrophils, 24 we compared the difference in IL-36R expression between blood and polyp neutrophils from CRSwNP patients by flow cytometry. CD16 
Siglec-8
-cells indicate neutrophil lineage. 10 We confirmed that few blood neutrophils had IL-36R expression; on the contrary, about 60% of neutrophils in DNPCs depleted of mononuclear cells expressed IL-36R (Fig 4, A) . Moreover, the expression intensity of IL-36R was markedly higher in polyp IL-36R 1 neutrophils than that in peripheral neutrophils (Fig 4, B) . The blood neutrophils from control subjects also lack IL-36R expression (data not shown). Using flow cytometry, we also confirmed that neutrophils were the principal cell type expressing IL-36R and mononuclear cells had no significant IL-36R expression in nasal polyps (see Fig E6 in this article' s Online Repository at www.jacionline.org). In order to validate our flow cytometric data, we analyzed IL-36R expression on blood monocytes, dendritic cells, and T cells. Consistent with previous reports, 24 we discovered IL-36R expression on blood monocytes and dendritic cells, but not CD3 1 CD8 -or CD3 J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5
Regulation of IL-36R expression in blood neutrophils
The upregulated expression of IL-36R on polyp neutrophils compared with their blood counterparts prompted us to study the regulation of IL-36R expression on neutrophils in inflammatory milieu. We found that IL-6, IL-1b, and Dermatophagoides pteronyssinus group 1 (Der p1) up-regulated the mRNA expression of IL-36R in purified blood neutrophils from controls (Fig 5, A) , and flow cytometric analysis confirmed the upregulation of IL-36R on peripheral blood neutrophils (Fig 5, C) . We further found that IL-6 and IL-1b additively or synergistically enhanced expression of IL-36R on peripheral neutrophils (Fig 5, B and  D) . Moreover, we found that the upregulation of IL-36R by Der p1 was abolished by a protease-activated receptor 2 (PAR-2) antagonist, suggesting a PAR-2-dependent effect for Der p1 (see Fig E9 in this article' s Online Repository at www. jacionline.org). No significant effect was observed for other stimulators tested (Fig 5, A) .
Nasal polyps display elevated elastase activity sufficient to activate IL-36g
Similar to the other members of IL-1 family, IL-36 cytokines are expressed as precursors and require proteolytic processing for activation. 38, 45, 46 At the concentration found in neutrophil degranulates, elastase has been identified as the principal IL-36g-activating enzyme. 38 Therefore, we sought to determine whether neutrophil elastase plays a key role in processing IL-36g in nasal polyps. First, we confirmed an upregulation of IL-36g in nasal epithelial cells from nasal polyps compared with those from controls but detected only in full-length form (Fig 6, A) . In contrast, in tissue homogenates, we did observe the presence of cleaved IL36g, suggesting a presence of proteolytic processing of secreted IL-36g in nasal polyps (Fig 6, A) . In addition, we found that both full-length and cleaved forms of IL-36g were significantly elevated in polyps compared to control tissues (Fig 6, A) . We next confirmed that neutrophils were the producer of elastase in polyps and the number of elastase positive neutrophils was significantly increased in CRSwNP compared with controls (Fig 6, B) . Furthermore, we eluted proteins from nasal tissues and found that polyp elutes displayed dramatically elevated elastase activity in comparison with controls, which was inhibited by elastase inhibitor (Fig 6, C) . Elastase activity did not differ between eosinophilic and noneosinophilic polyps (see Fig E10, A in this article's Online Repository at www.jacionline.org). We further found that IL-4, IL-17, and IFN-g had no significant effect on neutrophil elastase activity (Fig E10, B) . Consistent with previous reports, 38 we confirmed that recombined full-length IL-36g could be cleaved by elastase, which was abolished by elastase inhibitor and pan proteinase inhibitor cocktail (see Fig E11 in this article' s Online Repository at www.jacionline.org). Importantly, we found that polyp elutes were able to hydrolyze full-length IL-36g, which was inhibited by specific elastase inhibitor and pan protease inhibitor (Fig 6, D) . IL-36g can be activated and in turn promotes the production of IL-17A, MMP-9, and neutrophil chemokines in nasal polyps
Because it is difficult to isolate enough live neutrophils with high purity from polyp tissues, we used DNPCs depleted of mononuclear cells to investigate the function of IL-36g in CRSwNP. We measured some representative products of neutrophils to reflect their functions in host defense, inflammation, and tissue remodeling. 47 We found that N-terminally truncated IL36g (mature form) promoted the mRNA expression of IL-17A, matrix metalloproteinase 9 (MMP-9), CXCL1, CXCL2, and CXCL8, but not MPO, lactoferrin, MMP-2, or TGF-b2 in DNPCs (see Fig E12 in this article' s Online Repository at www. jacionline.org). Consistent with previous report, 45 the biological effect of truncated IL-36g could be observed at a concentration as low as 1 ng/mL (Fig E12) . Further analysis of protein levels in culture supernatants confirmed increased production of those mediators after stimulation (see Fig E13 in this article' s Online Repository at www.jacionline.org).
To test the hypothesis that IL-36g can be activated by neutrophil-derived elastase and thus exert its biological functions, we stimulated DNPCs with full-length IL-36g in the presence or absence of elastase inhibitor. In line with the findings in polyp elutes, we found that DNPC suspension had substantial elastase activity, which was dramatically inhibited by elastase inhibitor (see Fig E14 in this article' s Online Repository at www. jacionline.org). After stimulation with full-length IL-36g, we observed similar responses of DNPCs compared with truncated IL-36g treatment (Fig 7, A and B and Figs E12 and E13) . However, the effect of full-length IL-36g was abolished in the presence of elastase inhibitor, even when full-length IL-36g was given at a concentration as high as 100 ng/mL (Fig 7, A and B) . To specifically demonstrate the effect of IL-36g on polyp neutrophils, we examined IL-17A 1 neutrophils in DNPCs. Compared with the controls, full-length and truncated IL-36g upregulated IL-17A expression in neutrophils in DNPCs (see Fig E15 in this article's Online Repository at www.jacionline.org).
Glucocorticoids are unable to suppress the proinflammatory effect of IL-36g in nasal polyps Moreover, we investigated the effect of dexamethasone on IL36g function. We found that although dexamethasone suppressed IL-36g-induced MMP-9 mRNA expression, it was unable to inhibit IL-36g-induced production of IL-17A, CXCL1, CXCL2, and CXCL8 in DNPCs (Fig 7, C) . In addition, we did not observe significant difference in the effect of dexamethasone for DNPCs from eosinophilic and noneosinophilic polyps (see Fig E16 and  Table E2 in this article's Online Repository at www.jacionline.org).
Neutrophils are an important cellular source of IL-17A, MMP-9, and neutrophil chemokines in CRSwNP
Immunohistochemistry study showed that neutrophils were a cellular source of IL-17A, MMP-9, CXCL1, CXCL2, and CXCL8 in nasal polyps (see Fig E17 in this article' s Online Repository at www.jacionline.org). The numbers of neutrophils positive for those mediators were significantly increased in CRSwNP compared with controls (Fig 8) . 
DISCUSSION
The expression and function of IL-36 cytokine family in human airway diseases has been poorly investigated. Limited studies have shown that IL-36g induced production of neutrophil chemokines, CXCL1, CXCL2, and CXCL8, from macrophage cell line and lung fibroblasts in vitro. 19, 48 Intratracheal instillation of IL36a and IL-36g was able to promote neutrophil flux to the lungs of mice. 48, 49 Consistent with previous studies, 12, 13 this study confirmed upregulated neutrophilic inflammation and type-1/ type-17 responses in CRS patients in our area (Wuhan, China). Importantly, the present study provides the first description of the expression and function of IL-36 family, particularly IL36g, in CRS. We found that IL-36g was the most abundant member in CRS. Although both agonists and antagonists were upregulated in CRS, higher expression ratios of IL-36g/IL-36Ra and IL36g/IL-38 suggest an overall proinflammatory effect of IL-36 cytokine family in CRS.
We found that IL-36 cytokine family members had different cellular distribution in sinonasal mucosa. Consistent with IL-36g mRNA expression in bronchial epithelial cells, 19, 50 we discovered that IL-36g was predominantly produced by nasal epithelial cells, which were upregulated by proinflammatory and type-17 cytokines. In addition, IL-36g expression was discovered in inflammatory cells, and some of them have been identified as neutrophils. 44 Because our study also identified upregulated IL-36R expression on polyp neutrophils, those findings indicate an autoactivation mechanism of neutrophils in nasal polyps.
We next studied the function of IL-36g by using polyp tissues. IL-36R has previously been identified on resident cells and dendritic cells. 24, 25, [51] [52] [53] In the present study, we found that IL-36R was mainly expressed on neutrophils and to a lesser extent on eosinophils and dendritic cells, but not on lymphocytes, plasma cells, mast cells, or macrophages in nasal polyps. Although the majority of polyp neutrophils had IL-36R expression, few peripheral neutrophils had IL-36R expression. The almost absent expression of IL-36R on peripheral neutrophils is consistent with a previous report 24 and suggests a regulation of IL-36R expression on neutrophils by local inflammatory milieu. Indeed, we found that IL-36R expression on peripheral neutrophils could be upregulated by IL-1b, IL-6, and Der p1. The involvement of IL-1b, IL-6, and Der p1 in CRSwNP has been demonstrated previously. 30, 41, 54 House dust mites have been indicated to induce local IgE production and subsequent mast cell activation in CRSwNP. 30, 34 They can activate immune cells through activating PAR-2. [55] [56] [57] [58] In this study, we found that the PAR-2-dependent pathway was involved in Der p1-induced IL-36R expression on neutrophils. It should be noted that although these triggers significantly upregulated IL-36R expression on peripheral neutrophils, the expression level induced in vitro was much lower than that found in vivo. It indicates that other unexamined factors and/or synergistic effect of different mediators in the complex inflammatory network in CRSwNP may contribute to the further upregulation of IL-36R on neutrophils in vivo. An additive or synergistic effect between IL-6 and IL-1b discovered in this study can partially support this notion.
The roles of neutrophil in CRS have received little attention. Neutrophils play a key role in innate immunity through releasing antimicrobial products including MPO, lactoferrin, and proteases. 47 Neutrophil proteases can not only exert profound antimicrobial effects, but also hydrolyze inflammatory mediators and exacerbate tissue damage and inflammation. 38, 47 Like other members of the IL-1 family, the activity of IL-36 cytokines is strictly regulated through the N-terminal cleavage of the nascent peptide, resulting in an increase of their biological activity by up to 10,000-fold. 38, 45, 46 IL-36a, IL-36b, IL-36g, and IL-36Ra have recently been found to be activated differentially by the neutrophil granule-derived proteases cathepsin G, elastase, and proteinase-3. 38, 46 Neutrophil elastase has been identified as the major IL-36g-activating enzyme. 38 In line with those previous reports, 38 in this study, we presented circumstantial evidence that the increased activity of elastase in nasal polyps could facilitate the cleavage of full-length IL-36g produced by epithelial cells and thus lead to increased levels of cleaved IL-36g in polyp tissues. We finally explored the effect IL-36g on polyp neutrophils. In addition to releasing innate immunity mediators, neutrophils can produce TGF-b and MMP, therefore participating in tissue remodeling. 47 Neutrophils can also secrete chemokine CXCL1, CXCL2, and CXCL8 and thus create a self-perpetuating cycle. 47 We found that compared with truncated mature IL-36g, fulllength IL-36g exerted similar effects on DNPCs in promoting IL-17A, MMP-9, CXCL1, CXCL2, and CXCL8 production. However, the effects of full-length IL-36g were almost completely abolished in the presence of elastase inhibitor, confirming that the elastase is the major IL-36g -activating enzyme in polyps, and posttranslational processing of IL-36g is required to unleash its proinflammatory activity. 38 Our previous study reported increased infiltration of T H 17 and Tc17 cells in Chinese CRS. 8, 59 Neutrophils have been identified as a source of IL-17A in some infectious and autoimmune inflammation. [60] [61] [62] [63] Our current study demonstrated that neutrophils were also an important source of IL-17A in polyp tissues, accounting for about 25% of IL-17A 1 cells (data not shown), and IL-17A expression in neutrophils was promoted by IL-36g. On the other hand, we found that IL-17A upregulated IL-36g expression in nasal epithelial cells. These results underscore a positive cross-talk between epithelial cells and neutrophils in CRSwNP through the IL-17A-IL-36g axis. In addition, for the first time, we found that IL-36g was able to function on local neutrophils to induce the production of neutrophil chemokines and therefore sustained and exaggerated the neutrophilic inflammation in CRS. Nevertheless, it is noteworthy that the IL-36-neutrophil pathway may have different effects in different disease conditions. The resolution of inflammation mediated by IL-36R has been demonstrated in acute intestinal damage. 64 Thus more insight into the functions of the IL-36 pathway in different inflammatory responses may be critical for the development of proper therapeutic strategies aimed at manipulating this cytokine axis. 64 Very recently, Pothoven et al 10 found that neutrophils may contribute to impair epithelial barrier function in CRS. Together with our current findings, these data highlight an important, but previously neglected role of neutrophils in the pathogenesis of CRS. Neutrophilic inflammation has been associated with the corticosteroid resistance in patients with asthma and CRSwNP.
14,65 Here, we discovered that dexamethasone was unable to inhibit the proinflammatory effect of IL-36g on polyp neutrophils. Therefore IL-36g may contribute to neutrophil-mediated corticosteroid resistance in CRSwNP. However, the underlying mechanisms are worthy of further investigation.
One limitation of this study is that we only studied limited representative products of neutrophils. The effect of IL-36g on polyp neutrophils needs to be better studied by high-throughput techniques such as gene chips in the future. Given the limited samples obtained from CRSsNP patients, we did not confirm the effect of IL-36g on mucosal neutrophils in CRSsNP patients. Nevertheless, it can be expected that IL-36g plays a similar role in neutrophilic inflammation in this nonpolypoid form of CRS. Another limitation of our study is to use inferior turbinate mucosal samples as controls for nasal polyps. Although we did not observe significant difference in IL-36 expression between inferior turbinate mucosa and normal ethmoid mucosal samples with a small sample size (data not shown), previous studies demonstrated regional difference in expression of some immune mediators in the nasal cavity, 66 which argues for the caution to compare the expression of inflammatory mediators in different locations of nasal cavity. In addition, the effect of IL-36g on eosinophils and dendritic cells in CRS remains to be studied in further. Although increased infiltration of neutrophils has also been reported in white patients with CRSwNP, [10] [11] [12] polyps in Western patients more likely demonstrate eosinophil-biased inflammation without elevation of type-17 response. 12, 54 The contribution of IL-36 mediated reaction in polyps in Western patients deserves future studies.
In summary, our study shows that local inflammatory milieu may induce the IL-36g expression in nasal epithelial cells and IL-36R expression on neutrophils in CRS. IL-36g is activated by neutrophil-derived elastase and acts on neutrophils to further promote neutrophilic inflammation in CRS (see Fig E18 in this article's Online Repository at www.jacionline.org). Because the IL36g/IL-36R pathway may contribute to neutrophil-mediated corticosteroid resistance, targeting this pathway represents a promising novel strategy to alleviate inflammation in CRS.
Clinical implications: The IL-36g/IL-36R pathway may contribute to the development of neutrophilic inflammation and corticosteroid resistance through acting on neutrophils in CRS. Targeting this pathway may represent a promising novel strategy to alleviate inflammation in CRS.
